WASHINGTON — Federal health officials warned doctors Friday that the risk of a deadly brain inflammation linked to the multiple sclerosis treatment Tysabri increases with use of the drug.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
Tysabri has been plagued for years by rare cases of progressive multifocal leukoencephalopathy, or PML, which can cause swelling of the brain that is usually fatal. It is mostly seen in patients with immune deficiencies.
The biotech drug is marketed by Cambridge, Mass.-based Biogen Idec Inc. and Irish drugmaker Elan Corp. PLC, for multiple sclerosis and Crohn's disease.
The Food and Drug Administration said in a statement it has confirmed a total of 31 cases of PML since mid-2006. Eight of those patients have died, as of last month, according to the FDA. The agency posted updated labeling information for the drug to its Web site.
In the new labeling, FDA notes there have been no reports of PML in patients taking Tysabri for less than 12 months. In patients taking the drug for two to three years the rate of PML is one case per 1,000 patients.
The new labeling also warns of a complication of PML, known as Immune Reconstitution Inflammatory Syndrome, that can dramatically damage patients' health even after they have stopped taking Tysabri. The agency urges doctors to monitor patients for signs of inflammation.
Tysabri was approved in November 2004 and pulled from the market the next year due to PML reports. It was reintroduced in July 2006, and has been used by 66,000 people worldwide.
Shares of Biogen Idec Inc. fell 4 cents Friday to $53.06 in midday trading. Elan dipped 3 cents to $7.11.
Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.